Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

For the rising number of patients needing aortic reintervention, transcatheter aortic valve replacement (TAVR) explantation carried the highest mortality risk, two registry analyses affirmed. In ...

People with severe aortic stenosis, a condition where the heart’s aortic valve narrows and restricts blood flow, can already undergo a less invasive and faster procedure compared to traditional ...

Please provide your email address to receive an email when new articles are posted on . TAVR had similar clinical outcomes compared with surgery at 4 or 5 years in low-risk patients with severe aortic ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

The potential is high for TAVR adoption in emerging markets, according to Venkat Rajan, an analyst at Frost & Sullivan. “It is, however, coming in at a higher price point than traditional valves,” he ...

St. Luke’s Medical Center-Global City marks a significant milestone for its cardiovascular services, having successfully ...

The Federal Trade Commission (FTC) has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation, which is ...